Virtual Oncology In-service Colon Cancer: Individualizing Treatment Decisions

Part Two of The Validation Model^SM

Colorectal cancer (CRC) is the third most common type of cancer diagnosed in men and women in the United States. The 5-year survival rate for patients with these tumors is highly dependent on the stage of disease at presentation. Patients with stage IV disease have the most dismal 5-year survival rates (approximately 10%), and there is a major clinical need for improved treatment strategies for this most difficult-to-treat stage of disease. The changing landscape therapies for metastatic disease in recent years offers increased potential for prolongation of survival in such patients. Advances in tumor biology research have resulted in the development of targeted therapies to manage CRC. These therapies have been integrated into multiple treatment strategies for CRC and continue to be evaluated in different settings.

This case-based program will evaluate current and emerging methods to optimize CRC management in advanced disease. In particular, individualized treatment considerations will be discussed in the context of patients with potentially resectable liver metastases. The discussion will include surgical and neoadjuvant considerations and will apply current evidence to determine potential chemotherapeutic and targeted treatment options for these and other patients with advanced disease.

Available until January 31, 2012.
Physicians: 1.0 AMA PRA Category 1 Credit^™
Nurses: 1.0 contact hour

This activity is sponsored by SCEPTER™. This activity is co-provided by Global Education Group and SCEPTER.